Tag: Clinical Development
Beyond Random: Why Site-Specific Conjugation Is Redefining the ADC Therapeutic Window
Site-specific conjugation is reshaping how antibody-drug conjugates are engineered, replacing the structural heterogeneity of random conjugation with defined, homogeneous constructs. As multiple bioconjugation platforms...
AstraZeneca and Daiichi Sankyo Submit New BLA for Accelerated Approval of...
AstraZeneca and Daiichi Sankyo Submit New BLA for Accelerated Approval of Datopotamab Deruxtecan in advanced EGFR-mutated NSCLC
Successful Funding Round Expected to Accelerate ADC Therapeutics’ Clinical Development
Swiss Biotech company ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs for the treatment...
